ESGMay 8, 2026, 07:03 AM
Regeneron Named to Dow Jones Best-in-Class World Index
AI Summary
Regeneron Pharmaceuticals announced its inclusion in the Dow Jones Best-in-Class World Index and North America Index, recognizing its corporate sustainability performance. This marks its sixth consecutive year on the North America Index and highlights its commitment to responsibility, exemplified by offering a new gene therapy for genetic hearing loss for free in the U.S. The company also introduced new 2030 science-led responsibility goals and detailed progress in its 2025 Responsibility Report, while continuing its significant STEM education investments.
Key Highlights
- Named to Dow Jones Best-in-Class World Index for corporate sustainability.
- Named to Dow Jones Best-in-Class North America Index for 6th consecutive year.
- One of only 8 biotechnology companies globally on the World Index.
- One of only 4 U.S.-based biotechnology firms on the North America Index.
- Offering new gene therapy for genetic hearing loss for free in the U.S.
- Committed $300 million from 2017-2036 to STEM education programs.
- Ranks in top 10% of its industry across S&P Global, Sustainalytics, and ISS ESG.
- Named to Newsweek's America's Most Responsible Companies for 7th consecutive year.
Price Impact
More from REGN